Symptomatic Severe Aortic Stenosis
9
1
5
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
150%
6 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (9)
Evaluation of TAVR Using the NAVITOR Valve in a Global Investigation
Early System Experience With the Abbott Balloon-expandable TAVI System: First-In-Human Study
Early Feasibility Study (EFS) of Abbott's Balloon-expandable (BE) TAVI System for the Treatment of Severe, Symptomatic Aortic Stenosis
Surgical vs Transcatheter Aortic Valve Replacement in Young Patients
Portico Next Generation Approval Study
PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - S3 Intermediate
PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - XT Intermediate and High Risk
FlexNav EU CE Mark Study
PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - High Risk and Nested Registry 7